"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Descriptor ID |
D000970
|
MeSH Number(s) |
D27.505.954.248
|
Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 43 | 13 | 56 |
1995 | 29 | 16 | 45 |
1996 | 54 | 18 | 72 |
1997 | 53 | 22 | 75 |
1998 | 59 | 21 | 80 |
1999 | 75 | 26 | 101 |
2000 | 78 | 36 | 114 |
2001 | 82 | 31 | 113 |
2002 | 86 | 47 | 133 |
2003 | 145 | 60 | 205 |
2004 | 151 | 71 | 222 |
2005 | 156 | 62 | 218 |
2006 | 174 | 95 | 269 |
2007 | 198 | 113 | 311 |
2008 | 199 | 102 | 301 |
2009 | 202 | 120 | 322 |
2010 | 250 | 131 | 381 |
2011 | 253 | 144 | 397 |
2012 | 251 | 107 | 358 |
2013 | 242 | 116 | 358 |
2014 | 255 | 101 | 356 |
2015 | 289 | 121 | 410 |
2016 | 255 | 123 | 378 |
2017 | 231 | 98 | 329 |
2018 | 197 | 84 | 281 |
2019 | 166 | 77 | 243 |
2020 | 161 | 58 | 219 |
2021 | 177 | 54 | 231 |
2022 | 117 | 10 | 127 |
2023 | 126 | 4 | 130 |
2024 | 19 | 0 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
DePARylation is critical for S phase progression and cell survival. Elife. 2024 Apr 05; 12.
-
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525.
-
Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy. J Med Chem. 2024 Apr 11; 67(7):5333-5350.
-
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Apr; 125:102720.
-
First-in-human study of JNJ-67571244, a CD33 ? CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Clin Transl Sci. 2024 Mar; 17(3):e13742.
-
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol. 2024 Mar; 8:e2300124.
-
p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer. BMC Cancer. 2024 Feb 19; 24(1):233.
-
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med. 2024 Mar; 30(3):716-729.
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 Apr; 99(4):586-595.
-
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw. 2024 02; 22(1).